Tigenix NV

TiGenix develops and commercializes cell therapy products. Co.'s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. Co.'s main product, ChondroCelect, is a cell-based product that is used for cartilage repair in the knee. Co.'s is also involved in developing Cx601, which is in Phase III clinical trial for the treatment of complex perianal fistulas in patients suffering from Crohn's disease; Cx611, which has completed a Phase IIa clinical trial for the treatment of rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of autoimmune diseases.
  • TickerTGXSF
  • ISINBE0003864817
  • ExchangePink OTC Markets
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium

Analysts

Expert Corporate Governance Service (ECGS)

Proxy Report 07/06/2018

In general, TiGenix is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 4, the board of directors seeks approval of the Company's remuneration report. Since ECGS does not approve of LT incentive plans that do not operate one or more challenging performance conditions, it recommends to vote OPPOSE. On January 5, 2018, TiGenix announced an offer by Japan-based Takeda Pharmaceuticals Company Ltd, to acquire all its outstanding shares at a price of EUR 1.78 per share, which represents an enterprise value of approximate...

Lenny Van Steenhuyse ...
  • Ruben Devos

KBC Securities Morning Note 13-6-2018 TIG BB

Tigenix: CEO steps back Telecom: De Croo aims to keep spectrum free for 4th MNO

Alan Vandenberghe ...
  • Alexander Makar
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Wim Hoste

KBC Securities Morning Note 6-6-2018 AED BB, AGS BB, ARGX BB, GREEN BB, MDXH BB, TIG BB, UMI BB

Aedifica: German RoadRunner: € +44m boom Ageas: Feedback from CEO & CFO investor meetings Argenx: Bel20 biotech bonanza Greenyard: No surprises with full FY18/19 results MDxHealth: Licensing agreement with Philips Tigenix: Takeda owns 90.83% after 1st acceptance period Umicore: Capital Markets Event feedback

Termination of coverage

Edison Investment Research is terminating coverage on Tigenix (TIGB). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Proxy Report 07/06/2018

In general, TiGenix is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 4, the board of directors seeks approval of the Company's remuneration report. Since ECGS does not approve of LT incentive plans that do not operate one or more challenging performance conditions, it recommends to vote OPPOSE. On January 5, 2018, TiGenix announced an offer by Japan-based Takeda Pharmaceuticals Company Ltd, to acquire all its outstanding shares at a price of EUR 1.78 per share, which represents an enterprise value of approximate...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch